

Table of

CONTENTS

Message from CEO	1
Message from Director	2
Cancer Registry 2016 : Abstract	3
Annual Cancer Registry 2016	4
<i>Distribution of All Cancer by Age and Gender, The Top 10 Leading Site of Cancer, Method of Diagnosis, Staging, Type of Treatment, Patient Follow up, Patient Nationality, The Top 10 Leading Site of Thai Patient Cancer, The Top 10 Leading Site of Non-Thai Patient Cancer</i>	
Review of Breast Cancer	17
Review of Lung Cancer	22
Review of Colorectal Cancer	27
Review of Hepatobiliary Cancer	32
Review of Prostate Gland Cancer	37
Hematologic Malignancies 2016	42
Age Distribution in All Male Cancer Number of Case	58
Age Distribution in All Female Cancer Number of Case	60
Breast Cancer Survival	63
Colorectal Cancer Survival	65
Lung Cancer Survival	68



Message from

CEO

The cancer care is rapidly becoming much more integrated and specialized, as its field is about research, diagnosis and treatment. Oncology professionals need to both build their specialist knowledge and connect with the best practitioners in other disciplines worldwide.

Wattanosoth Hospital is dedicated to provide best cancer care. With affiliation program with MD Anderson Cancer Center and other institute, make it possible to keep the practice up to date. These days, awareness of cancer care expands to the cancer prevention, not only the best treatment. Therefore, the preventive sciences is developed and improved from the research in order to provide more comprehensive care.

The 2016 Cancer Registry Year Book by Wattanosoth Hospital has been systematically collected the vital data regarding cancer diseases with the most up-to-date research on cancer.



Poram Prasarttong-Osoth

Poramaporn Prasarttong-Osoth, M.D. FRCS (Glas)
Chief Operating Officer - BDMS
Chief Executive Officer - Group 1

Message from

Director



It is over one decade that Wattanosoth Cancer Hospital never stops developing and enhancing our services and technology for better patient cares.

In the meanwhile, we are continuously collecting data about our cancer patients in order to utilize the data for cancer research and hospital management and also to improve our cancer services from early cancer detection to treatment. We are delighted to share this information to the public to know more about cancer and have more understanding about cancer patients and encourage everyone to support patients to fight against their diseases.

On behalf of Wattanosoth Cancer Hospital, we aim to be the leading cancer center which have international standard. We hope this cancer registry would be useful for better cancer care.

A handwritten signature in black ink, appearing to read 'J. Khuhaprema', with a long horizontal line extending to the right.

Thiravud Khuhaprema, M.D., FRCST., FICS., Visiting Professor
Hospital Director, Wattanosoth Cancer Hospital
Bangkok Hospital Headquarter

Cancer Registry 2016 :

Abstract

The total of new cases diagnosed as a malignancy at Bangkok Hospital Headquarter (BHQ) is 1,977 cases (Tumor registry is 1,830 cases and Hematologic malignant is 147 cases). There was a little bit decrease in the total number as compared to 2,027 cases in 2015.

The sex ratio is 1:1. This age distribution has not changed since the year 2015. Patients who are between 45-69 y/o are the majority accounting for more than half of the total. The average age in male patients is 60-64 y/o which is slightly older than the female age of 45-49 y/o and 55-59 y/o.

Top 5 malignancies are:

- 1) Breast (included DCIS) - 27.54 percent
- 2) Lung - 10.38 percent
- 3) Colorectal - 9.62 percent
- 4) Liver & Hepatobiliary - 8.03 percent
- 5) Prostate - 6.83 percent

The trend for the top 5 malignancies has not changed over the past 10 years (2006 - 2015). For the past 10 years the top 5 have been: Breast, Colorectal, Lung, Liver & Hepatobiliary and Head & Neck cancer. However, when compared to last year, the overall number of cases in Breast cancer increased significantly by 14.54 percent, Lung cancer decreased by 7.31 percent, Colorectal cancer decreased by 20.00 percent, Liver & Hepatobiliary decreased by 2.00 percent and Prostate cancer increased by 11.60 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital Headquarter (BHQ) are: Stage 0 is 3.51 percent, Stage I is 23.62 percent, Stage II is 22.55 percent, Stage III is 19.04 percent, and Stage IV is 20.53 percent. Unspecified stage (due to lack of pertinent information) is 9.04 percent. And in cases of Brain cancer has no stage grouping applies in AJCC Staging manual is 1.70 percent. All results are similar to 2015 staging results.

Analysis of the primary treatments modalities indicates that surgery continues to be the majority (22 percent), followed by Radiation therapy (16 percent), Chemotherapy (4 percent), Concurrent chemo-radiation (3 percent) and Intervention treatment (3 percent)

Patients who are still living after diagnosis or treatment in 2016 is 41 percent, patients alive without disease are 14 percent, and patients who have died with cancer as the cause are 3 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 1:1 in year 2016 equal to the year 2015. The top 5 rankings of non-Thai patients are: Myanmar, Bangladesh, Cambodia, Oman and Kuwait, respectively.

The Top 5 malignancies of non-Thai patients are:

- 1) Breast (included DCIS) - 20.67 percent
- 2) Liver & Hepatobiliary - 8.85 percent
- 3) Colorectal - 8.75 percent
- 4) Prostate - 8.19 percent
- 5) Lung - 7.73 percent


It is the fifth time BHQ can follow the patients for 5 years and report the 5 years survival. We have shown and discussed the data of those survivors of top 3 cancers which are Breast, Lung and Colorectal in separated chapters.

WATTANOSOTH ANNUAL CANCER REGISTRY 2016


DISTRIBUTION OF ALL CANCER BY AGE AND GENDER (EXCLUDED HEMATOLOGIC MALIGNANCIES)

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	1	0.10	1	0.05
05 - 09	2	0.25	1	0.10	3	0.16
10 - 14	2	0.25	1	0.10	3	0.16
15 - 19	1	0.13	7	0.67	8	0.44
20 - 24	1	0.13	1	0.10	2	0.11
25 - 29	3	0.38	16	1.53	19	1.04
30 - 34	16	2.04	33	3.16	49	2.68
35 - 39	17	2.17	72	6.89	89	4.86
40 - 44	35	4.46	103	9.86	138	7.54
45 - 49	52	6.62	158	15.12	210	11.48
50 - 54	62	7.90	128	12.25	190	10.38
55 - 59	108	13.76	158	15.12	266	14.54
60 - 64	126	16.05	114	10.91	240	13.11
65 - 69	122	15.54	92	8.80	214	11.69
70 - 74	99	12.61	66	6.32	165	9.02
75 - 79	81	10.32	35	3.35	116	6.34
80 - 84	31	3.95	31	2.97	62	3.39
85 - 89	13	1.66	15	1.44	28	1.53
90 - 94	10	1.27	11	1.05	21	1.15
95 +	4	0.51	2	0.19	6	0.33
Total	785	100.00	1,045	100.00	1,830	100.00

2015




■ Male ■ Female




THE TOP 10 LEADING SITE OF CANCER IN BANGKOK HOSPITAL HEADQUARTER

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (include DCIS)	2	0.25	502	48.04	504	27.54
C33-C34	Lung	106	13.50	84	8.04	190	10.38
C18-C20	Colorectal	111	14.14	65	6.22	176	9.62
C22-C24	Liver & Hepatobiliary	103	13.12	44	4.21	147	8.03
C61	Prostate	125	15.92	0	0.00	125	6.83
C00-C14	Head & Neck	74	9.43	29	2.78	103	5.63
C73	Thyroid gland	25	3.18	78	7.46	103	5.63
C81-C85	Lymphoma	53	6.75	39	3.73	92	5.03
C43-C44	Skin	32	4.08	19	1.82	51	2.79
C53	Cervix	0	0.00	49	4.69	49	2.68


TOP 10 CANCER FOR ALL GENDER




2015




TOP 10 CANCER IN MALE




2015




TOP 10 CANCER IN FEMALE



2015




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Other = Previously diagnosed as Cancer from other Hospital but no documentation of diagnosis

STAGING



(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Stage 0 = Carcinoma in situ

None stage = In case of CA Brain

Unspecified stage = Incomplete staging due to insufficient patient information



TYPE OF TREATMENT

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	107	13.63	117	11.20	224	12.24
RT only	102	12.99	153	14.64	255	13.93
Brachytherapy	1	0.13	4	0.38	5	0.27
CT only	20	2.55	24	2.30	44	2.40
Targeted therapy	5	0.64	2	0.19	7	0.38
Hormonal therapy	3	0.38	6	0.57	9	0.49
Intervention	37	4.71	10	0.96	47	2.57
Nuclear medicine	8	1.02	31	2.97	39	2.13
Concurrent chemoradiation	23	2.93	17	1.63	40	2.19
SUR.+RT	13	1.66	8	0.77	21	1.15
SUR.+Brachytherapy	2	0.25	0	0.00	2	0.11
SUR.+CT	15	1.91	43	4.11	58	3.17
SUR.+Im	4	0.51	1	0.10	5	0.27
SUR.+H	0	0.00	18	1.72	18	0.98
SUR.+T	1	0.13	0	0.00	1	0.05
SUR.+I	1	0.13	1	0.10	2	0.11
SUR.+N	2	0.25	15	1.44	17	0.93
SUR.+Concurrent CT-RT	11	1.40	4	0.38	15	0.82
RT+Brachytherapy	0	0.00	5	0.48	5	0.27
RT+Concurrent CT-RT	0	0.00	1	0.10	1	0.05
CT+Concurrent CT-RT	6	0.76	2	0.19	8	0.44
RT+T	2	0.25	2	0.19	4	0.22
RT+CT	8	1.02	10	0.96	18	0.98
RT+CT+H	0	0.00	1	0.10	1	0.05
RT+H	5	0.64	4	0.38	9	0.49
RT+I	2	0.25	0	0.00	2	0.11
CT+T	0	0.00	2	0.19	2	0.11
CT+H	0	0.00	2	0.19	2	0.11
I+T	0	0.00	2	0.19	2	0.11
Concurrent CT-RT+ Brachytherapy	0	0.00	4	0.38	4	0.22
Concurrent CT-RT+T	1	0.13	0	0.00	1	0.05
SUR.+RT+CT	2	0.25	8	0.77	10	0.55
SUR.+RT+H	1	0.13	32	3.06	33	1.80
SUR.+CT+I	1	0.13	0	0.00	1	0.05
SUR.+CT+T	0	0.00	1	0.10	1	0.05
SUR.+CT+H	0	0.00	8	0.77	8	0.44
SUR.+RT+CT+T	0	0.00	2	0.19	2	0.11
SUR.+RT+CT+H	0	0.00	8	0.77	8	0.44

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
RT+Brachytherapy+CT	0	0.00	1	0.10	1	0.05
SUR.+CT+Concurrent CT-RT	2	0.25	3	0.29	5	0.27
SUR.+Concurrent CT-RT+ Brachytherapy	0	0.00	1	0.10	1	0.05
RT+Concurrent CT-RT+ Brachytherapy	0	0.00	1	0.10	1	0.05
SUR.+RT+CT+Concurrent CT-RT	0	0.00	1	0.10	1	0.05
Investigation	64	8.15	99	9.47	163	8.91
Supportive	4	0.51	4	0.38	8	0.44
PET/CT	99	12.61	111	10.62	210	11.48
Bone scan	60	7.64	86	8.23	146	7.98
Follow-up	3	0.38	3	0.29	6	0.33
2 nd Opinion	170	21.66	185	17.70	355	19.40
TBS scan	0	0.00	2	0.19	2	0.11
Total	785	100.00	1,045	100.00	1,830	100.00

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy


H (Hormone) = Hormonal therapy

T = Targeted therapy


I = Intervention

Im = Immunotherapy

TYPE OF PRIMARY MANAGEMENT (ALL PATIENT)




PATIENT FOLLOW UP



2nd Opinion only = Intend not to continue diagnosis or treatment at BMC

REFERRING HOSPITAL



BGH = Consult from Bangkok general hospital

WSH only = WATTANOSOTH HOSPITAL

BGH only = Not consult from Bangkok general hospital

PYT Group = Payathai hospital Group

SVH = SAMITVEJ SUKHUMVIT HOSPITAL

BPH = BANGKOK PATTAYA HOSPITAL

SNH = SAMITVEJ SRINAKARIN HOSPITAL

BNH = BNH HOSPITAL

Paolo Group = Paolo memorial hospital Group

BHN = BANGKOK HUAHIN HOSPITAL

BPK = BANGKOK PHUKET HOSPITAL

SSH = SAMITVEJ SRIRACHA HOSPITAL

BRH = BANGKOK RAYONG HOSPITAL

BCM = BANGKOK HOSPITAL CHIANGMAI

BCH = BANGKOK CHANTHABURI HOSPITAL

BMCO Myanmar = BANGKOK HOSPITAL OFFICE, MYANMAR

RPH = ROYAL PHNOM PENH HOSPITAL

BKH = BANGKOK RATCHASIMA HOSPITAL

BKN = BANGKOK HOSPITAL KHON KAEN

BTH = BANGKOK TRAT HOSPITAL

BSN = BANGKOK SANAMCHAN HOSPITAL

BHH = BANGKOK HATYAI HOSPITAL

PIH = PHUKET INTERNATIONAL HOSPITAL

STH = SAMITVEJ THONBURI HOSPITAL

BPD = BANGKOK PRAPRADAENG HOSPITAL


BPL = BANGKOK HOSPITAL PHITSANULOK

BUD = BANGKOK UDON HOSPITAL

RAH = ROYAL ANGLOR HOSPITAL

BMR = BANGKOK MUANGRAJ HOSPITAL


PATIENT NATIONALITY




THE TOP 10 LEADING SITE OF THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	0	0.00	282	49.47	282	31.23
C33-C34	Lung	48	14.41	60	10.53	108	11.96
C18-C20	Colorectal	52	15.62	30	5.26	82	9.08
C73	Thyroid gland	9	2.70	44	7.72	53	5.87
C00-C14	Head & Neck	37	11.11	16	2.81	53	5.87
C22-C24	Liver & Hepatobiliary	39	11.71	13	2.28	52	5.76
C81-C85	Lymphoma	20	6.01	19	3.33	39	4.32
C61	Prostate	37	11.11	0	0.00	37	4.10
C53	Cervix	0	0.00	24	4.21	24	2.66
C43-C44	Skin	8	2.40	11	1.93	19	2.10


TOP 10 CANCER OF THAI PATIENT ALL GENDER




2015




TOP 10 CANCER OF THAI PATIENT IN MALE




2015



TOP 10 CANCER OF THAI PATIENT IN FEMALE




2015




THE TOP 10 LEADING SITE OF NON-THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	2	0.37	220	40.52	222	20.67
C22-C24	Liver & Hepatobiliary	64	11.85	31	5.81	95	8.85
C18-C20	Colorectal	59	10.93	35	6.55	94	8.75
C61	Prostate	88	16.30	0	0.00	88	8.19
C33-C34	Lung	58	10.74	25	4.68	83	7.73
C81-C85	Lymphoma	33	6.11	20	3.75	53	4.93
C00-C14	Head & Neck	37	6.85	13	2.43	50	4.66
C73	Thyroid gland	16	2.96	34	6.37	50	4.66
C43-C44	Skin	24	4.44	8	1.50	32	2.98
C56	Ovary	0	0.00	27	3.24	27	2.51

TOP 10 CANCER OF NON-THAI PATIENT ALL GENDER




2015




OVERALL CANCER


TOP 10 CANCER OF NON-THAI PATIENT IN MALE




2015



TOP 10 CANCER OF NON-THAI PATIENT IN FEMALE



2015



BREAST CANCER : PATHOLOGY


Tumor site		Number
50.0	Nipple	8
50.1	Central portion of breast	2
50.2	Upper-inner quadrant of breast	34
50.3	Lower-inner quadrant of breast	14
50.4	Upper-outer quadrant of breast	116
50.5	Lower-outer quadrant of breast	29
50.8	Overlapping lesion of breast	29
50.9	Breast, NOS	272
Total		504

Pathology Report		Number
8000/3	Malignant neoplasm	123
8010/3	Carcinoma, NOS	1
8050/3	Papillary carcinoma, NOS	1
8140/3	Adenocarcinoma, NOS	3
8200/3	Adenoid cystic carcinoma	1
8211/3	Tubular carcinoma, NOS	3
8480/3	Mucinous carcinoma	4
8500/2	Ductal carcinoma in situ	41
8500/3	Infiltrating ductal carcinoma	308
8501/3	Comedocarcinoma	1
8520/2	Lobular carcinoma in situ	1
8520/3	Lobular carcinoma	12
8522/3	Infiltrating duct and lobular carcinoma	3
8523/3	Infiltrating duct mixed with other type of carcinoma	1
9020/3	Malignant phyllodes tumor	1
Total		504

AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	5	1.00	5	0.99
30 - 34	0	0.00	19	3.78	19	3.77
35 - 39	0	0.00	37	7.37	37	7.34
40 - 44	0	0.00	63	12.55	63	12.50
45 - 49	0	0.00	96	19.12	96	19.05
50 - 54	0	0.00	67	13.35	67	13.29
55 - 59	0	0.00	80	15.94	80	15.87
60 - 64	1	50.00	49	9.76	50	9.92
65 - 69	1	50.00	33	6.57	34	6.75
70 - 74	0	0.00	27	5.38	27	5.36
75 - 79	0	0.00	13	2.59	13	2.58
80 - 84	0	0.00	7	1.39	7	1.39
85 - 89	0	0.00	3	0.60	3	0.60
90 - 94	0	0.00	3	0.60	3	0.60
95 +	0	0.00	0	0.00	0	0.00
Total	2	100.00	502	100.00	504	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Total	
	Number	Percent
Biochemical	0	0.00
Other	14	5.04
Cytology	1	0.36
Histology	263	94.60
Imaging	0	0.00
Total	278	100.00

Other = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis

STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Stage 0 = Carcinoma in situ

Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Total	
	Number	Percent
SUR.only	54	19.42
RT only	94	33.81
CT only	8	2.88
Hormonal therapy	6	2.16
SUR.+RT	5	1.80
SUR.+CT	22	7.91
SUR.+H	18	6.47
RT+CT	5	1.80
RT+H	4	1.44
CT+T	1	0.36
CT+H	1	0.36
RT+CT+H	1	0.36
SUR.+RT+CT	7	2.52
SUR.+RT+H	32	11.51
SUR.+CT+T	1	0.36
SUR.+CT+H	8	2.88
SUR.+CT+Concurrent CT-RT	1	0.36
SUR.+RT+CT+T	2	0.72
SUR.+RT+CT+H	8	2.88
Total	278	100.00



SUR. = Surgery

CT = Chemotherapy


T = Targeted therapy

RT = External radiation therapy

H (Hormone) = Hormonal therapy



FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



LUNG CANCER : PATHOLOGY


Tumor site		Number
33.9	Trachea	1
34.0	Main bronchus	1
34.1	Upper lobe, lung	60
34.2	Middle lobe, lung	5
34.3	Lower lobe, lung	20
34.8	Overlapping lesion of lung	1
34.9	Lung, NOS	103
Total		191

Pathology Report		Number
M8000/3	Malignant neoplasm	54
M8010/3	Carcinoma, NOS	1
M8012/3	Large cell carcinoma, NOS	2
M8041/3	Small cell carcinoma, NOS	5
M8045/3	Combined small cell carcinoma	1
M8046/3	Non small cell carcinoma	20
M8070/3	Squamous cell carcinoma, NOS	16
M8071/3	Squamous cell carcinoma, keratinizing, NOS	1
M8072/3	Squamous cell carcinoma, large cell, nonkeratinizing	1
M8140/3	Adenocarcinoma, NOS	79
M8240/3	Carcinoid tumor, NOS	1
M8250/3	Bronchiolo-aveolar adenocarcinoma, NOS	3
M8480/3	Mucinous adenocarcinoma	4
M8481/3	Mucin-producing adenocarcinoma	1
M8550/3	Acinar cell carcinoma	1
M9050/3	Mesothelioma, malignant	1
Total		191

AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	0	0.00	0	0.00	0	0.00
35 - 39	0	0.00	4	4.71	4	2.09
40 - 44	4	3.77	2	2.35	6	3.14
45 - 49	2	1.89	11	12.94	13	6.81
50 - 54	5	4.72	7	8.24	12	6.28
55 - 59	16	15.09	14	16.47	30	15.71
60 - 64	19	17.92	8	9.41	27	14.14
65 - 69	24	22.64	10	11.76	34	17.80
70 - 74	16	15.09	14	16.47	30	15.71
75 - 79	11	10.38	1	1.18	12	6.28
80 - 84	6	5.66	8	9.41	14	7.33
85 - 89	0	0.00	3	3.53	3	1.57
90 - 94	2	1.89	3	3.53	5	2.62
95 +	1	0.94	0	0.00	1	0.52
Total	106	100.00	85	100.00	191	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	3	6.00	5	13.16	8	9.09
Cytology	1	2.00	0	0.00	1	1.14
Histology	46	92.00	33	86.84	79	89.77
Imaging	0	0.00	0	0.00	0	0.00
Total	50	100.00	38	100.00	88	100.00

Other = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	3	15.00	9	23.68	12	13.64
RT only	27	54.00	19	50.00	46	52.27
Brachytherapy	0	0.00	1	2.63	1	1.14
CT only	9	18.00	2	5.26	11	12.50
Targeted therapy	1	2.00	1	2.63	2	2.27
Intervention	1	2.00	0	0.00	1	1.14
Concurrent CT-RT	2	4.00	1	2.63	3	3.41
SUR.+RT	1	2.00	0	0.00	1	1.14
RT+CT	5	10.00	1	2.63	6	6.82
RT+T	1	2.00	2	5.26	3	3.41
CT+T	0	0.00	1	2.63	1	1.14
Concurrent CT-RT+CT	0	0.00	1	2.63	1	1.14
Total	50	109.00	38	100.00	88	100.00



SUR. = Surgery


RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy



FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



COLORECTAL CANCER : PATHOLOGY


Tumor site		Number
C18.0	Cecum colon	3
C18.1	Appendix	2
C18.2	Ascending colon	12
C18.3	Hepatic flexure of colon	4
C18.4	Transverse colon	7
C18.5	Splenic flexure of colon	1
C18.6	Descending colon	5
C18.7	Sigmoid colon	33
C18.8	Overlapping lesion of colon	2
C18.9	Colon, NOS	25
C19.9	Rectosigmoid colon	6
C20.9	Rectum	76
Total		176

Pathology Report		Number
M8000/3	Malignant neoplasm	51
M8010/3	Carcinoma, NOS	1
M814/3	Adenocarcinoma	116
M8480/3	Mucinous adenocarcinoma	6
M8490/3	Adenocarcinoma signet ring cell type	2
Total		176

AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	1	0.90	0	0.00	1	0.57
25 - 29	0	0.00	1	1.54	1	0.57
30 - 34	2	1.80	0	0.00	2	1.14
35 - 39	5	4.50	4	6.15	9	5.11
40 - 44	5	4.50	2	3.08	7	3.98
45 - 49	10	9.01	4	6.15	14	7.95
50 - 54	8	7.21	7	10.77	15	8.52
55 - 59	16	14.41	12	18.46	28	15.91
60 - 64	19	17.12	12	18.46	31	17.61
65 - 69	18	16.22	7	10.77	25	14.20
70 - 74	13	11.71	5	7.69	18	10.23
75 - 79	9	8.11	5	7.69	14	7.95
80 - 84	2	1.80	2	3.08	4	2.27
85 - 89	1	0.90	1	1.54	2	1.14
90 - 94	1	0.90	2	3.08	3	1.70
95 +	1	0.90	1	1.54	2	1.14
Total	111	100.00	65	100.00	176	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	3	6.25	1	3.03	4	4.94
Cytology	0	0.00	0	0.00	0	0.00
Histology	45	93.75	32	96.97	77	95.06
Imaging	0	0.00	0	0.00	0	0.00
Total	48	100.00	33	100.00	81	100.00

Other = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	14	29.17	12	36.36	26	32.10
RT only	11	22.92	4	12.12	15	18.52
CT only	1	2.08	1	3.03	2	2.47
Targeted therapy	1	2.08	0	0.00	1	1.23
Concurrent CT-RT	4	8.33	2	6.06	6	7.41
SUR.+CT	12	25.00	9	27.27	21	25.93
SUR.+Concurrent CT-RT	1	2.08	2	6.06	3	3.70
CT+Concurrent CT-RT	1	2.08	0	0.00	1	1.23
SUR.+RT+CT	1	2.08	1	3.03	2	2.47
SUR.+CT+I	1	2.08	0	0.00	1	1.23
SUR.+CT+Concurrent CT-RT	1	2.08	2	6.06	3	3.70
Total	48	100.00	33	100.00	81	100.00




SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



HEPATOBIILIARY CANCER : PATHOLOGY


Tumor site		Number
C22.0	Liver	117
C22.1	Liver (Pathology is M8160/3)	21
C24.0	Common bile duct	3
C24.1	Ampullar of vater	6
Total		147

Pathology Report		Number
M8000/3	Malignant neoplasm	96
M8010/3	Carcinoma, NOS	1
M8140/3	Adenocarcinoma, NOS	9
M8160/3	Cholangiocarcinoma	9
M8170/3	Hepatocellular carcinoma, NOS	31
M8970/3	Hepatoblastoma	1
Total		147

AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	1	2.27	1	0.68
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	1	0.97	0	0.00	1	0.68
35 - 39	4	3.88	0	0.00	4	2.72
40 - 44	3	2.91	4	9.09	7	4.76
45 - 49	4	3.88	4	9.09	8	5.44
50 - 54	9	8.74	0	0.00	9	6.12
55 - 59	23	22.33	8	18.18	31	21.09
60 - 64	15	14.56	7	15.91	22	14.97
65 - 69	13	12.62	7	15.91	20	13.61
70 - 74	10	9.71	6	13.64	16	10.88
75 - 79	10	9.71	1	2.27	11	7.48
80 - 84	7	6.80	5	11.36	12	8.16
85 - 89	2	1.94	1	2.27	3	2.04
90 - 94	1	0.97	0	0.00	1	0.68
95 +	1	0.97	0	0.00	1	0.68
Total	103	100.00	44	100.00	147	100.00

■ Male ■ Female




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	1	1.85	0	0.00	1	1.35
Cytology	1	1.85	0	0.00	1	1.35
Histology	28	51.85	8	40.00	36	48.65
Imaging	24	44.44	12	60.00	36	48.65
Total	54	100.00	20	100.00	74	100.00

Other = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	6	11.11	2	10.00	8	10.81
RT only	3	5.56	2	10.00	5	6.76
CT only	1	1.85	0	0.00	1	1.35
Targeted therapy	1	1.85	1	5.00	2	2.70
Intervention	36	66.67	10	50.00	46	62.16
SUR.+RT	1	1.85	0	0.00	1	1.35
SUR.+CT	1	1.85	1	5.00	2	2.70
SUR.+I	1	1.85	1	5.00	2	2.70
RT+CT	0	0.00	1	5.00	1	1.35
RT+I	2	3.70	0	0.00	2	2.70
RT+T	1	1.85	0	0.00	1	1.35
I+T	0	0.00	2	10.00	2	2.70
SUR.+CT+Concurrent CT-RT	1	1.85	0	0.00	1	1.35
Total	54	100.00	20	100.00	74	100.00



SUR. = Surgery

RT = External radiation therapy


CT = Chemotherapy

T = Targeted therapy

I = Intervention



FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




PROSTATE GLAND CANCER : PATHOLOGY

Tumor site		Number
C61.9	Prostate gland	125
Total		125

Pathology Report		Number
M8000/3	Malignant neoplasm	40
M8120/3	Transitional cell carcinoma, NOS	1
M8140/3	Adenocarcinoma, NOS	47
M8550/3	Acinar adenocarcinoma	37
Total		125

AGE AND GENDER

Age	Male	
	Number	Percent
00 - 04	0	0.00
05 - 09	0	0.00
10 - 14	0	0.00
15 - 19	0	0.00
20 - 24	0	0.00
25 - 29	0	0.00
30 - 34	0	0.00
35 - 39	0	0.00
40 - 44	0	0.00
45 - 49	0	0.00
50 - 54	3	2.40
55 - 59	11	8.80
60 - 64	24	19.20
65 - 69	32	25.60
70 - 74	21	16.80
75 - 79	21	16.80
80 - 84	6	4.80
85 - 89	4	3.20
90 - 94	3	2.40
95 +	0	0.00
Total	125	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male	
	Number	Percent
Biochemical	0	0.00
Other	2	5.13
Cytology	0	0.00
Histology	36	92.31
Imaging	1	2.56
Total	39	100.00

Other = Previously diagnosed as Head and Neck cancer from other Hospital but no document of Pathology


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male	
	Number	Percent
SUR.only	7	17.95
RT only	18	46.15
Brachytherapy	1	2.56
Hormone therapy	3	7.69
RT+H	5	12.82
SUR.+RT	2	5.13
SUR.+Brachytherapy	2	5.13
SUR.+RT+H	1	2.56
Total	39	100.00




SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




HEMATOLOGIC MALIGNANCIES 2016

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES

Code	Disease	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C81	Hodgkin's disease	10	11.36	13	22.03	23	15.65
C82	Follicular NHL	6	6.82	3	5.08	9	6.12
C83	Diffuse NHL	24	27.27	17	28.81	41	27.89
C84	Peripheral and cutaneous T-cell lymphoma	6	6.82	1	1.69	7	4.76
C85	Other and unspecified type of NHL	7	7.95	5	8.47	12	8.16
C90	Multiple myeloma	15	17.05	7	11.86	22	14.97
C91	Lymphoid leukemia	3	3.41	1	1.69	4	2.72
C92	Myeloid leukemia	17	19.32	12	20.34	29	19.73
Total		88	100.00	59	100.00	147	100.00


All Patient



DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE AND GENDER


Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	1	1.69	1	0.68
10 - 14	0	0.00	2	3.39	2	1.36
15 - 19	1	1.14	1	1.69	2	1.36
20 - 24	4	4.55	2	3.39	6	4.08
25 - 29	4	4.55	3	5.08	7	4.76
30 - 34	7	7.95	1	1.69	8	5.44
35 - 39	5	5.68	3	5.08	8	5.44
40 - 44	11	12.50	2	3.39	13	8.84
45 - 49	7	7.95	1	1.69	8	5.44
50 - 54	8	9.09	8	13.56	16	10.88
55 - 59	8	9.09	3	5.08	11	7.48
60 - 64	9	10.23	11	18.64	20	13.61
65 - 69	6	6.82	7	11.86	13	8.84
70 - 74	9	10.23	7	11.86	16	10.88
75 - 79	6	6.82	4	6.78	10	6.80
80 - 84	2	2.27	3	5.08	5	3.40
85 - 89	1	1.14	0	0.00	1	0.68
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	88	100.00	59	100.00	147	100.00

■ Male ■ Female




PATIENT NATIONALITY

Patient Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Thai	31	35.23	30	50.85	61	41.50
Non-Thai	57	64.77	29	49.15	86	58.50
Total	88	100.00	59	100.00	147	100.00



PATIENT FOLLOW UP STATUS




LYMPHOMA

AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	1	2.56	1	1.09
10 - 14	0	0.00	2	5.13	2	2.17
15 - 19	1	1.89	1	2.56	2	2.17
20 - 24	3	5.66	2	5.13	5	5.43
25 - 29	4	7.55	1	2.56	5	5.43
30 - 34	3	5.66	1	2.56	4	4.35
35 - 39	3	5.66	2	5.13	5	5.43
40 - 44	7	13.21	2	5.13	9	9.78
45 - 49	5	9.43	0	0.00	5	5.43
50 - 54	4	7.55	7	17.95	11	11.96
55 - 59	3	5.66	2	5.13	5	5.43
60 - 64	6	11.32	5	12.82	11	11.96
65 - 69	4	7.55	3	7.69	7	7.61
70 - 74	5	9.43	6	15.38	11	11.96
75 - 79	3	5.66	3	7.69	6	6.52
80 - 84	1	1.89	1	2.56	2	2.17
85 - 89	1	1.89	0	0.00	1	1.09
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	53	100.00	39	100.00	92	100.00


LYMPHOMA

■ Male ■ Female



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	0	0.00	3	7.69	3	3.26
≥ 15 yr.	53	100.00	36	92.31	89	96.74
Total	53	100.00	39	100.00	92	100.00

<15 yr.
3%




≥ 15 yr.
97%

METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology	6	42.86	11	57.89	17	51.52
Histology + Flow cytometry	5	35.71	4	21.05	9	27.27
Histology + Immunohistochemistry	2	14.29	3	15.79	5	15.15
Histology + Flow cytometry + Chromosome	1	7.14	1	5.26	2	6.06
Total	14	100.00	19	100.00	33	100.00


STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	1	7.14	1	5.26	2	6.06
Radiotherapy	2	14.29	6	31.58	8	24.24
Chemotherapy	8	57.14	9	47.37	17	51.52
Bone Marrow Transplantation	1	7.14	0	0.00	1	3.03
Surgery + Chemotherapy	1	7.14	1	5.26	2	6.06
Chemotherapy + Radiotherapy	0	0.00	2	10.53	2	6.06
Chemotherapy + Bone Marrow Transplantation	1	7.14	0	0.00	1	3.03
Total	14	100.00	19	100.00	33	100.00




PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive with disease	13	92.86	19	100.00	32	96.97
Alive without disease	1	7.14	0	0.00	1	3.03
Total	14	100.00	19	100.00	33	100.00

Alive without disease

3%



Alive with disease


97%

MULTIPLE MYELOMA


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	2	13.33	0	0.00	2	9.09
35 - 39	1	6.67	0	0.00	1	4.55
40 - 44	0	0.00	0	0.00	0	0.00
45 - 49	1	6.67	1	14.29	2	9.09
50 - 54	3	20.00	0	0.00	3	13.64
55 - 59	1	6.67	1	14.29	2	9.09
60 - 64	2	13.33	4	57.14	6	27.27
65 - 69	1	6.67	0	0.00	1	4.55
70 - 74	1	6.67	1	14.29	2	9.09
75 - 79	3	20.00	0	0.00	3	13.64
80 - 84	0	0.00	0	0.00	0	0.00
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	15	100.00	7	100.00	22	100.00

■ Male ■ Female



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	0	0.00	0	0.00	0	0.00
≥ 15 yr.	15	100.00	7	100.00	22	100.00
Total	15	100.00	7	100.00	22	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology	2	40.00	3	100.00	5	62.50
Histology + Flow cytometry	2	40.00	0	0.00	2	25.00
Histology + Immunohistochemistry	1	20.00	0	0.00	1	12.50
Total	5	100.00	3	100.00	8	100.00


TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	1	20.00	0	0.00	1	12.50
Radiotherapy	1	20.00	1	33.33	2	25.00
Chemotherapy	2	40.00	1	33.33	3	37.50
Chemotherapy + Radiotherapy	1	20.00	0	0.00	1	12.50
Chemotherapy + Bone Marrow Transplantation	0	0.00	1	33.33	1	12.50
Total	5	100.00	3	100.00	8	100.00



PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive with disease	5	100.00	3	100.00	8	100.00
Alive without disease	0	0.00	0	0.00	0	0.00
Total	5	100.00	3	100.00	8	100.00




LEUKEMIA


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	1	5.00	0	0.00	1	3.03
25 - 29	0	0.00	2	15.38	2	6.06
30 - 34	2	10.00	0	0.00	2	6.06
35 - 39	1	5.00	1	7.69	2	6.06
40 - 44	4	20.00	0	0.00	4	12.12
45 - 49	1	5.00	0	0.00	1	3.03
50 - 54	1	5.00	1	7.69	2	6.06
55 - 59	4	20.00	0	0.00	4	12.12
60 - 64	1	5.00	2	15.38	3	9.09
65 - 69	1	5.00	4	30.77	5	15.15
70 - 74	3	15.00	0	0.00	3	9.09
75 - 79	0	0.00	1	7.69	1	3.03
80 - 84	1	5.00	2	15.38	3	9.09
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	20	100.00	13	100.00	33	100.00

■ Male ■ Female



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	0	0.00	0	0.00	0	0.00
≥ 15 yr.	20	100.00	13	100.00	33	100.00
Total	20	100.00	13	100.00	33	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology+Flow cytometry	2	66.67	1	50.00	3	60.00
Histology + Flow cytometry + Immunohistochemistry	1	33.33	1	50.00	2	40.00
Total	3	100.00	2	100.00	5	100.00

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy	2	66.67	2	100.00	4	80.00
Chemotherapy + Bone Marrow Transplantation	1	33.33	0	0.00	1	20.00
Total	3	100.00	2	100.00	5	100.00


Chemotherapy + Bone Marrow
Transplantation
20%



Chemotherapy
80%

PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive with disease	3	100.00	2	100.00	5	100.00
Total	3	100.00	2	100.00	5	100.00



AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	00 -04	05 -09	10 -14	15 -19	20 -24	25 -29	30 -34	35 -39	40 -44	45 -49	50 -54	55 -59	60 -64	65 -69	70 -74	75 -79	80 -84	85 -89	90 -95	95+	Total	%
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.11
C01-C02	Tongue	0	0	0	0	0	0	0	0	3	2	5	0	3	0	0	0	0	0	0	0	13	1.49
C03	Gum	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.11
C04	Floor of mouth	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	2	0.23
C05	Palate	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	2	0.23
C06	Other part of mouth	0	0	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	5	0.57
C07	Parotid gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.11
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	3	0.34
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	2	0.23
C11-C14	Head and Neck	0	0	0	0	0	0	4	1	5	9	6	6	3	4	4	2	0	0	0	0	44	5.04
C15	Esophagus	0	0	0	0	0	0	0	0	0	0	1	4	3	2	2	1	0	0	0	0	13	1.49
C16	Stomach	0	0	0	0	0	0	0	1	0	2	2	2	5	1	4	2	0	0	0	0	19	2.18
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C18-C20	Colon and Rectum	0	0	0	0	1	0	2	5	10	8	16	19	18	13	9	2	1	1	1	1	111	12.71
C21	Anus	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	2	0.23
C22-C24	Liver and Hepatobiliary	0	0	0	0	0	0	1	4	3	4	9	23	15	13	10	7	2	1	1	1	103	11.80
C25	Pancreas	0	0	0	0	0	0	0	0	0	2	1	3	4	2	2	1	3	0	0	0	18	2.06
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2	0.23
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.11
C32	Larynx	0	0	0	0	0	0	0	0	0	2	2	3	5	1	4	2	1	1	1	1	23	2.63
C33-C34	Lung	0	0	0	0	0	0	0	0	4	2	5	16	19	24	16	11	6	0	2	1	106	12.14
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.11
C38	Mediastinum	0	0	0	0	0	1	0	0	0	0	2	2	0	0	2	0	0	0	0	0	7	0.80
C40-C41	Bone	0	0	1	0	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	0	4	0.46
C43-C44	Skin	0	0	0	0	0	0	0	0	2	3	1	4	1	6	8	4	1	1	1	0	32	3.67
C48	Retroperitoneum	0	0	0	0	0	0	0	0	1	0	0	0	1	2	0	0	0	0	0	0	4	0.46
C49	Connective tissue	0	0	0	0	0	1	0	1	0	1	2	1	2	1	0	1	0	0	0	0	10	1.15
C50	Breast	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2	0.23

Code	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C54	Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	2	0.23
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	3	11	24	32	21	21	6	4	3	0	125	14.32
C62	Testis	0	0	1	0	0	1	2	1	1	1	0	0	0	0	0	0	0	0	0	0	7	0.80
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	0	0	0	0	1	2	3	5	4	8	1	1	3	0	1	0	0	29	3.32
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	2	0.23
C67	Bladder	0	0	0	0	0	0	1	0	0	3	2	4	4	6	5	8	4	1	1	0	39	4.47
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	2	0	1	0	0	1	1	0	0	2	1	2	0	0	1	0	0	0	0	11	1.26
C72	Spinal cord and GNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	0	0	0	4	2	5	3	2	0	4	3	0	2	0	0	0	0	25	2.86
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other and endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other and ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primarysite	0	0	0	0	0	0	0	0	1	3	0	2	2	1	2	1	1	0	0	0	13	1.49
C81	Hodgkin's disease	0	0	0	0	2	4	1	0	0	1	0	0	1	0	0	1	0	0	0	0	10	1.15
C82	Follicular NHL	0	0	0	0	0	0	0	1	2	0	2	0	0	0	1	0	0	0	0	0	6	0.69
C83	Diffuse NHL	0	0	0	0	1	0	2	1	2	4	1	1	3	3	3	1	1	1	0	0	24	2.75
C84	Peripheral and cutaneous T-cell lymphoma	0	0	0	0	0	0	0	0	1	0	1	1	1	1	1	0	0	0	0	0	6	0.69
C85	Other and unspecified type of NHL	0	0	0	1	0	0	0	1	2	0	0	1	1	0	0	1	0	0	0	0	7	0.80
C90	Multiple myeloma	0	0	0	0	0	0	2	1	0	1	3	1	2	1	1	3	0	0	0	0	15	1.72
C91	Lymphoid leukemia	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	3	0.34
C92	Myeloid leukemia	0	0	0	0	1	0	2	1	4	1	1	3	1	1	1	0	1	0	0	0	17	1.95
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
All ICD Group		0	2	2	2	5	7	23	22	46	59	70	116	135	128	110	85	33	14	10	4	873	100.00



AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBERS OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	00	05	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	90	95+	Total	%
		04-09	14-19	24-29	34-39	44-49	54-59	64-69	74-79	84-89	94-99	95+											
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.09
C01-C02	Tongue	0	0	0	0	0	0	1	0	0	0	2	0	0	1	0	0	1	0	0	0	5	0.45
C03	Gum	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	3	0.27
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.09
C05	Palate	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	2	0.18
C06	Other part of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C07	Parotid gland	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	2	0.18
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C09	Tonsil	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	3	0.27
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head and Neck	0	0	0	1	0	0	1	1	1	4	1	0	2	1	0	0	0	0	0	0	12	1.09
C15	Esophagus	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1	1	0	0	0	6	0.54
C16	Stomach	0	0	0	0	0	0	1	2	1	0	1	3	1	2	3	1	1	0	0	0	16	1.45
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.09
C18-C20	Colon and Rectum	0	0	0	0	1	0	4	2	4	2	7	12	12	7	5	5	2	1	2	1	65	5.89
C21	Anus	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.09
C22-C24	Liver and Hepatobiliary	1	0	0	0	0	0	0	4	4	0	8	7	7	7	6	1	5	1	0	0	44	3.99
C25	Pancreas	0	0	0	0	0	1	0	1	1	2	2	3	2	3	2	0	1	0	0	0	18	1.63
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	2	0.18
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.09
C32	Larynx	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.09
C33-C34	Lung	0	0	0	0	0	0	4	2	11	7	14	8	10	14	1	8	3	3	0	0	85	7.70
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C38	Mediastinum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C40-C41	Bone	0	0	1	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0.36
C43-C44	Skin	0	0	0	0	0	0	0	1	1	1	3	2	1	2	0	1	1	3	2	1	19	1.72
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	3	0.27
C49	Connective tissue	0	0	0	0	0	0	0	1	1	0	0	3	2	2	0	1	0	0	0	0	10	0.91
C50	Breast	0	0	0	0	4	19	34	54	86	65	69	43	33	23	13	7	3	3	0	0	456	41.30

Code	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-95	95+	Total	%
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.09
C52	Vagina	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	2	0.18
C53	Cervix	0	0	0	0	2	2	4	6	8	9	6	7	3	0	1	1	0	0	0	0	49	4.44
C54	Corpus uteri	0	0	0	0	0	0	0	3	4	3	4	6	5	4	2	1	0	0	0	0	32	2.90
C55	Uterus	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.09
C56	Ovary	0	0	0	0	1	1	2	5	9	6	6	1	6	0	0	0	0	0	0	0	37	3.35
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	0	0	1	0	1	0	4	2	2	1	0	1	1	1	1	0	0	14	1.27
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C67	Bladder	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	1	0	0	5	0.45
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C70-C71	Brain	0	1	0	2	0	0	0	0	0	0	2	0	0	1	0	2	1	0	0	0	9	0.82
C72	Spinal cord and CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	2	1	4	6	15	11	10	9	6	3	0	2	0	0	0	0	0	78	7.07
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C75	Other and endocrine gland	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.09
C76	Other and ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primarysite	0	0	0	0	1	0	0	0	1	1	0	2	1	1	0	0	0	0	1	0	8	0.72
C81	Hodgkin's disease	0	0	1	1	2	0	1	2	1	0	2	0	1	1	1	0	0	0	0	0	13	1.18
C82	Follicular NHL	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	3	0.27
C83	Diffuse NHL	0	0	1	0	0	0	0	0	1	0	4	2	2	1	4	1	1	0	0	0	17	1.54
C84	Peripheral and cutaneous T-cell lymphoma	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09
C85	Other and unspecified type of NHL	0	0	0	0	1	0	0	0	0	1	0	1	0	1	1	0	0	0	0	0	5	0.45
C90	Multiple myeloma	0	0	0	0	0	0	0	0	0	1	0	0	5	0	1	0	0	0	0	0	7	0.63
C91	Lymphoid leukemia	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.09
C92	Myeloid leukemia	0	0	0	0	2	0	1	0	0	0	1	1	4	0	1	2	0	0	0	0	12	1.09
D05	Ductal carcinoma in situ of breast	0	0	0	0	1	0	3	9	10	2	11	6	0	4	0	0	0	0	0	0	46	4.17
All ICD Group		1	1	4	8	3	19	34	75	105	159	136	161	125	99	73	39	34	15	11	2	1,104	100.00



A Report on Cancer Survival in Wattanosoth Cancer Hospital

This report on cancer survival is based on an analysis of data of top 3 common cancers (i.e., breast, colorectal and lung cancer) in Wattanosoth Cancer Hospital (WSH). The data has been collected by the hospital tumor registry. The cancer patients were diagnosed during a 12-month period from January 1 to December 31, 2011. All of them received treatment at WSH and were prospectively followed-up up to December 31, 2016 (5-year follow-up period).

Survival rates were estimated by Kaplan-Meier method. The survival rates of subgroups of cancer patients categorized by age (aged ≤ 50 and > 50 years old), sex (male and female) and stage of cancer at diagnosis (stage 1 - 4) were analyzed for comparison.

As this report is hospital registry-based cancer survival analysis, the study may have limitations related to endpoint data and sample size. The observed survival rates are estimated by method which cumulative probability of survival is calculated at consecutive one-month intervals after diagnosis. The information used included death from the cancer and other causes; lost to follow-up before observation period ended; and follow-up ends due to observation period ended. Therefore survival estimated may be biased if the proportion of lost to follow-up or other causes of death is high. Survival rate estimated from small numbers of cases can provide misleading results and may have wide confidence intervals. In addition to compare survival rate between different groups, test for statistical significant may be misleading.

Breast Cancer Survival

160 cases were diagnosed breast cancer during January 1 to December 31, 2011. At the time of diagnosis, 55 (34.8%) of them were at stage 1, 48 (30.4%) at stage 2, 36 (22.8%) at stage 3, and 19 (12.0%) at stage 4. Their average age was 55.9 years old (SD \pm 13.1). 63 (39.6%) of them aged \leq 50 years old and 96 (60.4%) aged $>$ 50 years old.

The median follow-up period of these breast cancer patients was 48 months (25th - 75th percentile: 10.5 - 60 months). During the 5-year follow-up period, 6 of them were dead and 1 were lost to follow-up.

The overall observed survival rate of the breast cancer patients at 5-year follow-up period was 95.5% (95%CI: 90.1 - 97.9) (Fig.1). The survival seems to have no difference between the age group of $>$ 50 and \leq 50 years old, of which the survival rate was 93.6% (95%CI: 85.2 - 97.3), and 98.1% (95%CI: 87.4 - 99.7) respectively (Fig.2).

The observed survival of the early stage breast cancers, i.e., stage 1 and 2 was 100.0% and 100.0% respectively, while the survival of the late stages, i.e., stage 3 and 4 was 92.6% (95%CI: 73.4 to 98.1) and 53.4% (95%CI: 9.1 to 84.9) respectively (Fig. 3). The survival rate tends to be lower in the late stage breast cancers.



Figure 1. Overall observed survival rate of the breast cancer patients in WSH during 5-year follow-up period




Figure 2. Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old




Figure 3. Observed survival rate of the breast cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

Colorectal Cancer Survival

89 cases were diagnosed colorectal cancer during January 1 to December 31, 2011. At the time of diagnosis, 7 (8.3%) of them were at stage 1, 20 (23.8%) at stage 2, 32 (38.1%) at stage 3, and 25 (29.8%) at stage 4. Their average age was 62.5 years old (SD \pm 13.8). 17 (19.1%) of them aged \leq 50 years old and 72 (80.9%) aged $>$ 50 years old. Among of them, there were 51 (57.3%) males and 38 (42.7%) females.

The median follow-up period of these colorectal cancer patients was 25 months (25th - 75th percentile: 7 - 60 months). During the 5-year follow-up period, 9 of them were dead and 1 were lost to follow-up.

The overall observed survival rate of the colorectal cancer patients at 5-year follow-up period was 84.1% (95%CI: 70.6 - 91.7) (Fig.1). The survival among the male patients was 81.7% (95%CI: 65.2 - 90.9) and female was 88.7% (95%CI: 61.4 - 97.1) (Fig 2). The male patients seem to have lower observed survival rate. The survival seems to have no difference between the age group of $>$ 50 and \leq 50 years old, of which the survival rate was 84.8% (95%CI: 69.9 - 92.7) and 86.5% (95%CI: 55.8 - 96.5) respectively (Fig. 3).

The observed survival of early stage colorectal cancers, i.e., stage 1 and 2 was 100.0% and 93.7% (95%CI: 63.2 - 99.1) respectively, while the survival of the late stages, i.e., stage 3 and 4 was 84.4% (95%CI: 47.2 - 96.3) and 50.9% (95%CI: 19.2 - 75.8) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced. Especially in the stage 4, the survival was substantially decreased.



Figure 1. Overall observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period




Figure 2. Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by gender (male and female)




Figure 3. Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old




Figure 4. Observed survival rate of the colorectal cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

Lung Cancer Survival

97 cases were diagnosed lung cancer during January 1 to December 31, 2011. At the time of diagnosis, 10 (11.4%) of them were at stage 1, 3 (3.4%) at stage 2, 17 (19.3%) at stage 3, and 58 (65.9%) at stage 4. Their average age was 65.3 years old (SD \pm 10.4). 8 (8.2%) of them aged \leq 50 years old and 89 (91.2%) aged $>$ 50 years old. Among of them, there were 64 (66.0%) males and 33 (34.0%) females.

The median follow-up period of these lung cancer patients was 12 months (25th - 75th percentile: 4 - 25). During the 5-year follow-up period, 22 of them were dead and 1 were lost to follow-up.

The observed survival rate of the lung cancer patients at 5-year follow-up period was 44.1% (95%CI: 24.5 - 62.1) (Fig.1). The survival seems to have no difference between male and female patients, of which the survival rate was 57.0% (95%CI: 35.9 - 73.5) and 22.9% (95%CI: 1.5 - 59.5) respectively (Fig 2). The survival of patients aged $>$ 50 and \leq 50 years old was 52.0% (95%CI: 31.7 - 68.8) and 0.0% respectively (Fig. 3).

The observed survival rate of early stage lung cancers, i.e., stage 1 and 2 was 83.3% (95%CI: 27.3 - 97.5) and 0.0% respectively while the survival of late stages, i.e., stage 3 and 4 was 46.4% (95%CI: 0.9 - 88.3) and 17.7% (95%CI: 1.4 - 49.3) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced.



Figure 1. Overall observed survival rate of the lung cancer patients in WSH during 5-year follow-up period




Figure 2. Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by gender (male and female)




Figure 3. Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by age group of ≤ 50 and > 50 years old

Kaplan-Meier survival estimates by Stage




Figure 4. Observed survival rate of the lung cancer patients in WSH during 5-year follow-up period by stage of the cancer at diagnosis (stage 1- 4)

Our Cancer Center



Fountain of Victory

**Making Cancer Care
Beyond Excellence**